Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 9/20 | 0.88 |
| ▸ | NFE2L2 | Q16236 | 9/20 | 0.88 |
| ▸ | PPARG | P37231 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL702692 | 0.89 | KEAP1 (0.68) | KEAP1NFE2L2PPARGL3MBTL1 | |
| SCHEMBL6204399 | 0.87 | KEAP1 (0.67) | KEAP1NFE2L2PPARGKMT2ACA12 | |
| SCHEMBL3366459 | 0.87 | KEAP1 (0.86) | KEAP1NFE2L2PPARGTSHR | |
| SCHEMBL1632092 | 0.87 | KEAP1 (0.86) | KEAP1NFE2L2PPARGKMT2A | |
| SCHEMBL14502622 | 0.86 | KEAP1 (0.66) | KEAP1NFE2L2PPARGKMT2ACA12 | |
| SCHEMBL5568657 | 0.85 | NR1I2 (0.65) | KEAP1NFE2L2PPARGTSHRKMT2A | |
| SCHEMBL7775104 | 0.85 | KEAP1 (0.72) | KEAP1NFE2L2PPARGL3MBTL1 | |
| SCHEMBL7813073 | 0.85 | KEAP1 (0.68) | KEAP1NFE2L2PPARGKMT2A | |
| SCHEMBL1039483 | 0.84 | KEAP1 (0.81) | KEAP1NFE2L2PPARGTSHR | |
| SCHEMBL5572766 | 0.84 | KEAP1 (0.75) | KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1457487-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE CIS-PIPERIDINE DERIVATIVES | Toray Fine Chemicals Co., Ltd. (JP) | 2004-09-15 | — | — | EP | claimed |
| US-20040171836-A1 | Method for producing optical-active cis-piperidine derivatives | TORAY FINE CHEMICALS CO., LTD., A CORPORATION OF JAPAN, (JP) | 2004-09-02 | — | — | US | claimed |
| JP-4169558-A | — | — | None | — | — | JP | disclosed |
| JP-4013659-A | — | — | None | — | — | JP | disclosed |
| JP-61093145-A | — | — | None | — | — | JP | disclosed |
| US-20210024461-A1 | (S)-CSA Salt Of S-Ketamine, (R)-CSA Salt Of S-Ketamine And Processes For The Preparation Of S-Ketamine | JANSSEN PHARMACEUTICA NV (BE) | 2021-01-28 | — | — | US | disclosed |
| EP-3294704-B1 | (S)-CSA SALT OF S-KETAMINE, (R)-CSA SALT OF S-KETAMINE AND PROCESSES FOR THE PREPARATION OF S-KETAMINE | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-30 | — | — | EP | disclosed |
| US-20160332962-A1 | (S)-CSA SALT OF S-KETAMINE, (R)-CSA SALT OF S-KETAMINE AND PROCESSES FOR THE PREPARATION OF S-KETAMINE | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-17 | — | — | US | disclosed |
| EP-2423211-B1 | PROCESSES FOR PRODUCING (1S,6S)- OR (1R,6R)-CIS-2,8-DIAZABICYCLO[4.3.0]NONANE AND INTERMEDIATE THEREOF | KANEKA CORP (JP) | 2014-04-16 | — | — | EP | disclosed |
| EP-2423211-A1 | PROCESSES FOR PRODUCING (1S,6S)- OR (1R,6R)-CIS-2,8-DIAZABICYCLO[4.3.0]NONANE AND INTERMEDIATE THEREOF | Kaneka Corporation (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-20090198052-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE PIPERIDINE COMPOUNDS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-08-06 | — | — | US | disclosed |
| WO-1999006433-A1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | disclosed |
| US-5792869-A | REACTING PIPERAZINE DERIVATIVE WITH SULFONAMIDE DERIVATIVE OF OPTICALLY ACTIVE AMINO ACID, PRECIPITATING LESS SOLUBLE SALT, SEPARATING, DECOMPOSING TO DESIRED DIASTEREOMER | YAMAKAWA CHEMICAL INDUSTRY CO., LTD (JP) | 1998-08-11 | — | — | US | disclosed |
| US-5792869-A | REACTING PIPERAZINE DERIVATIVE WITH SULFONAMIDE DERIVATIVE OF OPTICALLY ACTIVE AMINO ACID, PRECIPITATING LESS SOLUBLE SALT, SEPARATING, DECOMPOSING TO DESIRED DIASTEREOMER | YAMAKAWA CHEMICAL INDUSTRY CO., LTD (JP) | 1998-08-11 | — | — | US | disclosed |
| EP-0710652-B1 | Process for preparing optically active piperazine derivatives and intermediates for preparation | YAMAKAWA CHEMICAL IND (JP) | 1998-03-04 | — | — | EP | disclosed |
| EP-0710652-A2 | Process for preparing optically active piperazine derivatives and intermediates for preparation | YAMAKAWA CHEMICAL INDUSTRY CO., LTD. (JP) | 1996-05-08 | — | — | EP | disclosed |
| EP-0710652-A2 | Process for preparing optically active piperazine derivatives and intermediates for preparation | YAMAKAWA CHEMICAL INDUSTRY CO., LTD. (JP) | 1996-05-08 | — | — | EP | disclosed |
| JP-H04169558-A | PRODUCTION OF OPTICALLY ACTIVE 1,2-PROPANEDIAMINE | TORAY IND INC | 1992-06-17 | — | — | JP | disclosed |
| JP-H0413659-A | PRODUCTION OF OPTICALLY ACTIVE 1-BENZYL-3-HYDROXYPYRROLIDINE | TORAY IND INC | 1992-01-17 | — | — | JP | disclosed |
| JP-S6193145-A | METHOD OF SEPARATING AMINO ACID ENANTIOMER BY CHROMATOGRAPHY | FUNAKOSHI YAKUHIN KK | 1986-05-12 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024461-A1 | (S)-CSA Salt Of S-Ketamine, (R)-CSA Salt Of S-Ketamine And Processes For The Preparation Of S-Ketamine | STS, SRR, SRM | KEAP1 811/4885NFE2L2 4269/4885PPARG 4382/4885 |
| US-20040171836-A1 | Method for producing optical-active cis-piperidine derivatives | TYR, DDC, TARBP1 | KEAP1 3681/4885NFE2L2 3843/4885PPARG 461/4885 |
| US-20090198052-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE PIPERIDINE COMPOUNDS | SNCA, SYNJ1, KCNH2 | KEAP1 3555/4885NFE2L2 2194/4885PPARG 2218/4885 |
| US-20160332962-A1 | (S)-CSA SALT OF S-KETAMINE, (R)-CSA SALT OF S-KETAMINE AND PROCESSES FOR THE PREPARATION OF S-KETAMINE | STS, SRR, SRM | KEAP1 782/4885NFE2L2 4245/4885PPARG 4389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.